CD38-NAD(+) Axis Regulates Immunotherapeutic Anti-Tumor T Cell Response
Shilpak Chatterjee,Anusara Daenthanasanmak,Paramita Chakraborty,Megan W. Wyatt,Payal Dhar,Shanmugam Panneer Selvam,Jianing Fu,Jinyu Zhang,Hung Nguyen,Inhong Kang,Kyle Toth,Mazen Al-Homrani,Mahvash Husain,Gyda Beeson,Lauren Ball,Kristi Helke,Shahid Husain,Elizabeth Garrett-Mayer,Gary Hardiman,Meenal Mehrotra,Michael I. Nishimura,Craig C. Beeson,Melanie Gubbels Bupp,Jennifer Wu,Besim Ogretmen,Chrystal M. Paulos,Jeffery Rathmell,Xue-Zhong Yu,Shikhar Mehrotra
DOI: https://doi.org/10.1016/j.cmet.2017.10.006
IF: 29
2018-01-01
Cell Metabolism
Abstract:Heightened effector function and prolonged persistence, the key attributes of Th1 and Th17 cells, respectively, are key features of potent anti-tumor T cells. Here, we established ex vivo culture conditions to generate hybrid Th1/17 cells, which persisted long-term in vivo while maintaining their effector function. Using transcriptomics and metabolic profiling approaches, we showed that the enhanced anti-tumor property of Th1/17 cells was dependent on the increased NAD(+)-dependent activity of the histone deacetylase Sirt1. Pharmacological or genetic inhibition of Sirt1 activity impaired the antitumor potential of Th1/17 cells. Importantly, T cells with reduced surface expression of the NADase CD38 exhibited intrinsically higher NAD(+), enhanced oxidative phosphorylation, higher glutaminolysis, and altered mitochondrial dynamics that vastly improved tumor control. Lastly, blocking CD38 expression improved tumor control even when using Th0 anti-tumor T cells. Thus, strategies targeting the CD38-NAD(+) axis could increase the efficacy of antitumor adoptive T cell therapy.